Cargando…
The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic ar...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971687/ https://www.ncbi.nlm.nih.gov/pubmed/2372496 |
_version_ | 1782134963846512640 |
---|---|
author | Goldberg, J. A. Kerr, D. J. Watson, D. G. Willmott, N. Bates, C. D. McKillop, J. H. McArdle, C. S. |
author_facet | Goldberg, J. A. Kerr, D. J. Watson, D. G. Willmott, N. Bates, C. D. McKillop, J. H. McArdle, C. S. |
author_sort | Goldberg, J. A. |
collection | PubMed |
description | The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery. |
format | Text |
id | pubmed-1971687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1990 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19716872009-09-10 The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. Goldberg, J. A. Kerr, D. J. Watson, D. G. Willmott, N. Bates, C. D. McKillop, J. H. McArdle, C. S. Br J Cancer Research Article The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery. Nature Publishing Group 1990-06 /pmc/articles/PMC1971687/ /pubmed/2372496 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Goldberg, J. A. Kerr, D. J. Watson, D. G. Willmott, N. Bates, C. D. McKillop, J. H. McArdle, C. S. The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
title | The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
title_full | The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
title_fullStr | The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
title_full_unstemmed | The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
title_short | The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
title_sort | pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971687/ https://www.ncbi.nlm.nih.gov/pubmed/2372496 |
work_keys_str_mv | AT goldbergja thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT kerrdj thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT watsondg thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT willmottn thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT batescd thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT mckillopjh thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT mcardlecs thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT goldbergja pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT kerrdj pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT watsondg pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT willmottn pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT batescd pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT mckillopjh pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases AT mcardlecs pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases |